By Keith S. Wexler, MBA, Maternal Fetal Medicine, Prenatal Diagnosis and Biotech/Life Sciences Consultant, GENASSIST, Inc.
Paul Wexler, M.D., F.A.C.O.G., Medical Director, GENASSIST, Inc.
Clinical Professor, Department of OB/GYN, University of Colorado Health Sciences Center
Clinical Professor, Division of Genetics/Dept. of Pediatrics, Univ. of Colorado/The Children’s Hospital
Pancreatic Cancer represents one of the most difficult cancers to diagnose and treat. Early symptoms may be vague and mimic symptoms originating from other organs e.g. gall bladder, stomach and bowel. However, we are beginning to see an increasing number of patients who have been able to realize remissions or cures.
Most cases are not known to be familial, however, some families with familial mutations for Lynch Syndrome or Breast Cancer may also have one or more relatives who do get Pancreatic Cancer.
Hereditary testing for Pancreatic Cancer susceptibility may also identify some patients at risk for breast, ovarian, and possibly other cancers.
Mutations in the PALB2, P53, BRCA2 genes can help identify some individuals and families at risk for these diseases. Negative testing will not guarantee the absence of risk but positive mutational analysis can increase the degree of surveillance.
Signs and Symptoms: Dark urine, jaundice, abdominal pain, back pain, light colored stools, itching, nausea and vomiting, venous thrombosis, enlarged gall bladder, diabetes, enlarged liver, ulcers, weight loss, diarrhea, red and warm skin, wheezing, increased heart rate and diarrhea.
- Intraoperative proton beam
- Epidermal Growth Factor Receptor Targeting
- Anti-Angiogenesis Factor
- Stroma (supportive tissue) target drugs to allow better access
- Immune Therapy
- Cancer Vaccines
- Drugs that target Immune System Checkpoints